Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Escudier, B. [1 ]
Rini, B., I [2 ]
Hutson, T. E. [3 ]
Gore, M. [4 ]
Oudard, S. [5 ]
Tarazi, J. [6 ]
Rosbrook, B. [6 ]
Williams, J. A. [7 ]
Kim, S. [6 ]
Motzer, R. J. [8 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44106 USA
[3] Baylor Sammons Texas Oncol Phys Assoc, Dept Oncol, Dallas, TX USA
[4] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
[5] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[6] Pfizer Oncol, Dept Clin Oncol, San Diego, CA USA
[7] Pfizer Oncol, Dept Translat Oncol, San Diego, CA USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2012年 / 11卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E81 / U450
页数：2
相关论文
共 50 条
  • [1] Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
    Rini, B. I.
    Escudier, B.
    Tomczak, P.
    Kaprin, A.
    Hutson, T. E.
    Szczylik, C.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)
    Cella, D.
    Escudier, B.
    Rini, B.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Motzer, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S224 - S224
  • [3] Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
    Cella, D.
    Escudier, B.
    Rini, B. I.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Axitinib versus sorafenib as second-line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.
    Qin, Shukui
    Bi, Feng
    Cheng, Ying
    Guo, Jun
    Ren, Xiu Bao
    Huang, Yiran
    Wang, Jinwan
    Ben, Yong
    Kim, Sinil
    Tang, Jie
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    Motzer, Robert J.
    Escudier, Bernard
    Tomczak, Piotr
    Hutson, Thomas E.
    Michaelson, M. Dror
    Negrier, Sylvie
    Oudard, Stephane
    Gore, Martin E.
    Tarazi, Jamal
    Hariharan, Subramanian
    Chen, Connie
    Rosbrook, Brad
    Kim, Sinil
    Rini, Brian I.
    LANCET ONCOLOGY, 2013, 14 (06): : 552 - 562
  • [6] Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.
    Rini, Brian I.
    Escudier, Bernard J.
    Michaelson, M. Dror
    Negrier, Sylvie
    Gore, Martin Eric
    Oudard, Stephane
    Clark, Joseph
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Kim, Sinil
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] Safety and efficacy of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by duration of prior therapy: Subanalyses from a phase III trial
    Escudier, B.
    Motzer, R. J.
    Lim, H. Y.
    Porfiri, E.
    Zalewski, P.
    Kannourakis, G.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S673 - S674
  • [9] Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
    Qin, Shukui
    Bi, Feng
    Jin, Jie
    Cheng, Ying
    Guo, Jun
    Ren, Xiubao
    Huang, Yiran
    Tarazi, Jamal
    Tang, Jie
    Chen, Connie
    Kim, Sinil
    Ye, Dingwei
    ONCOTARGETS AND THERAPY, 2015, 8 : 1363 - 1373
  • [10] AXIS trial data confirm axitinib as second-line option for mRCC
    Sarah Payton
    Nature Reviews Urology, 2013, 10 (6) : 308 - 308
12345